Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 27;31(3):381-387.
doi: 10.5606/tgkdc.dergisi.2023.24329. eCollection 2023 Jul.

Survival of pleurectomy-decortication and hyperthermic chemotherapy in mesothelioma

Ayşe Gül Ergönül  1 , Sercan Aydın  2 , Seda Kahraman Aydın  1 , Tevfik İlker Akçam  1 , Ali Özdil  1 , Kutsal Turhan  1 , Alpaslan Çakan  1 , Ufuk Çağırıcı  1
Affiliations

Survival of pleurectomy-decortication and hyperthermic chemotherapy in mesothelioma

Ayşe Gül Ergönül et al. Turk Gogus Kalp Damar Cerrahisi Derg. .

Abstract

Background: This study aims to evaluate overall survival, diseasefree survival, and prognostic factors in patients undergoing pleurectomy-decortication and hyperthermic intrathoracic chemotherapy with the diagnosis of malignant pleural mesothelioma.

Methods: Between January 2020 and November 2021, a total of 53 patients (27 males, 26 females; mean age: 58.1±1.3 years; range, 39 to 81 years) who underwent pleurectomy-decortication and hyperthermic intrathoracic chemotherapy with the diagnosis of malignant pleural mesothelioma were retrospectively analyzed. Data including characteristics, comorbidities, postoperative complications, recurrence and mortality status of the patients were recorded. Overall survival and disease-free survival and prognostic factors were evaluated.

Results: The median disease-free survival was 11.67 months and the median overall survival was 24.60 months. The median disease-free survival was 8.80 months in men and 13.17 months in women, indicating a statistically significant difference as it showed that recurrence was detected earlier in male patients (p=0.037). The median disease-free survival and overall survival was 6.13 months and 11.70 in cases diagnosed with biphasic mesothelioma, respectively, while it was 11.67 months and 25.46 months in cases with epithelial mesothelioma, respectively. Pathological subtype was found to be an effective prognostic factor for both survival (p=0.049 and p<0.001, respectively).

Conclusion: Hyperthermic intrathoracic chemotherapy following cytoreductive surgery is a preferable and tolerable method in the treatment of malignant pleural mesothelioma. While evaluating surgical indications, it should be kept in mind that cases with epithelial mesothelioma may benefit more from surgical treatment.

Keywords: Chemotherapy; chest; mesothelioma; pleural disease; survival..

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Figures

Figure 1
Figure 1. Relationship between mesothelioma subtype and disease-free survival.
Figure 2
Figure 2. Relationship between mesothelioma subtype and overall survival.
See this image and copyright information in PMC

References

    1. Zucali PA, Ceresoli GL, De Vincenzo F, Simonelli M, Lorenzi E, Gianoncelli L, et al. Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev. 2011;37:543–558. doi: 10.1016/j.ctrv.2011.01.001. - DOI - PubMed
    1. Tuğ T, Tuğ E. Asbest maruziyeti ve malign mezotelyoma'da etiyopatogenez ve epidemiyolojik özellikler; tümör supresör gen ilişkileri. Turkiye Klinikleri J Med Sci. 2005;25:436–444.
    1. Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, et al. Malignant pleural mesothelioma: An update on investigation, diagnosis and treatment. Eur Respir Rev. 2016;25:472–486. doi: 10.1183/16000617.0063-2016. - DOI - PMC - PubMed
    1. Opitz I. Management of malignant pleural mesotheliomaThe European experience. S238-52J Thorac Dis. 2014;6 Suppl 2 doi: 10.3978/j.issn.2072-1439.2014.05.03. - DOI - PMC - PubMed
    1. Mujoomdar AA, Sugarbaker DJ. Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2008;20:298–304. doi: 10.1053/j.semtcvs.2008.11.002. - DOI - PubMed

LinkOut - more resources